VTT is searching for new drug targets for prostate cancer in the new IMI PREDECT project
Launched in 2007, the Innovative Medicines Initiative (IMI) aims to support more efficient, earlier diagnostics and the development of better medicines for patients by removing research bottlenecks in the drug development pipeline. PREDECT, one of IMI’s new projects, is developing novel models for breast, prostate and lung cancers. The Work Package 2 - coordinated by VTT Technical Research Centre of Finland - focuses on target validation and improved model systems for prostate cancer.Being the largest public-private research partnership in the pharmaceutical sector, IMI aims to speed up